Combination therapy of pions and SPG (Sonifilan, Schizophyllan), a biological response modifier for mouse tumor systems.
Female C3H mice aged 8-10 weeks with transplanted KHT sarcoma or SCCVII tumor were used to investigate the antitumor effect of SPG (Sonifilan, Schizophyllan) alone and in combination with local irradiation of pions with 4 fractions of 400 cGy (total 1600 cGy). Daily doses of 10 mg/kg of SPG were given intramuscularly to the mice bearing KHT sarcoma for 14 consecutive days from day 7, and to mice bearing SCCVII tumor for 20 consecutive days from day 7 and thereafter three times a week for another 2 weeks. The antitumor effect was evaluated by the changes in tumor volume, survival curves, and the number of pulmonary metastatic nodules on the surface of the lungs. SPG failed to exert any antitumor effect and any life-prolonging effect for the KHT sarcoma. As for SCCVII tumor, in the group treated with pions and SPG, tumor growth decreased significantly (p less than 0.01) compared with the group treated with pion only, and life prolonging effect and metastasis-suppressing effect were also observed (p less than 0.04). In conditions of minimal residual disease brought about by pion irradiation, the adjuvant effect of a Biological Response Modifier (BRM) SPG may prove to be a promising method of cancer therapy for some tumors.
Ogawa
Y
Y
Developmental Radiotherapy, Cancer Control Agency of British Columbia, Vancouver, Canada.
Goodman
G B
GB
Chaplin
D J
DJ
Grulkey
W
W
Lam
G K
GK
D000818:Animals; D003131:Combined Modality Therapy; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008651:Mesons; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000532:radiotherapy / Q000628:therapy*; D011882:Radiotherapy, High-Energy; D012566:Sizofiran / Q000627:therapeutic use*
D006025:Glycosaminoglycans; D007155:Immunologic Factors; D012566:Sizofiran